Met Life Investment Management, LLC Jounce Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$6.01 - $8.54 $10,042 - $14,270	-1,671 Closed	0 $0
Q4 2021 May 17, 2024	SELL	$7.11 - $9.64 $78,039 - $105,808	-10,976 Reduced 86.79%	1,671 $13,000
Q4 2021 Jun 21, 2023	BUY	$7.11 - $9.64 $11,880 - $16,108	1,671 New	1,671 $13,000
Q4 2021 Mar 22, 2023	SELL	$7.11 - $9.64 $78,039 - $105,808	-10,976 Reduced 86.79%	1,671 $13,000
Q4 2021 Feb 15, 2022	SELL	$7.11 - $9.64 $78,039 - $105,808	-10,976 Reduced 86.79%	1,671 $14,000
Q3 2021 May 17, 2024	BUY	$5.04 - $8.73 $63,740 - $110,408	12,647 New	12,647 $93,000
Q3 2021 Jun 21, 2023	BUY	$5.04 - $8.73 $63,740 - $110,408	12,647 New	12,647 $93,000
Q3 2021 Mar 22, 2023	BUY	$5.04 - $8.73 $63,740 - $110,408	12,647 New	12,647 $93,000
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $63,740 - $110,408	12,647 New	12,647 $94,000
Q2 2018 Aug 15, 2018	SELL	$7.27 - $21.88 $51,849 - $156,048	-7,132 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.4 - $28.4 $95,568 - $202,548	7,132 New	7,132 $159,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.